The Nico Misleh Podcast
The Nico Misleh Podcast
Podcast Description
Welcome to the Nico Misleh Podcast, where patient care meets the realities of building a thriving practice. Hosted by nurse practitioner and entrepreneur Nico Misleh, this podcast offers insights into hormone replacement therapy, cash-based clinics, and the business of wellness. Whether you're a provider navigating clinical care or an aspiring entrepreneur, Nico shares honest conversations, practical advice, and expert interviews to guide you. Tune in to redefine success for your patients and yourself.
Podcast Insights
Content Themes
The podcast covers a variety of themes including hormone replacement therapy, the dynamics of cash-based clinics, and effective marketing strategies. Episodes explore topics such as balancing family and business, scaling a healthcare practice, and maintaining authentic patient relationships, with concrete examples like personal journeys in HRT and actionable strategies for attracting clients without social media reliance.
Welcome to the HRT University® Podcast, where patient care meets the realities of building a thriving practice. Hosted by nurse practitioner and entrepreneur Nico Misleh, this podcast offers insights into hormone replacement therapy, cash-based clinics, and the business of wellness. Whether you’re a provider navigating clinical care or an aspiring entrepreneur, Nico shares honest conversations, practical advice, and expert interviews to guide you. Tune in to redefine success for your patients and yourself.
Learn more about Nico and becoming an expert in HRT: https://bit.ly/4twBb0D
There is a group of providers who oppose compounded HRT medications on principle. Their argument sounds evidence-based. Standardization. Regulation. Studies. It holds up until you look at what they are actually prescribing.
In this episode, Nico Misleh, MSN FNP-C, walks through two clinical examples that expose the internal contradiction: the Androgel problem, in which providers who oppose compounding are instructing female patients to eyeball a fraction of a men’s testosterone gel; and the progesterone problem, in which the FDA-only framework leaves patients with no option except a pharmacologically distinct synthetic progestin when commercial dose ranges fall short.
The episode also goes into the regulatory reality of 503A and 503B compounding pharmacies, the neurosteroid pharmacology that makes progesterone and synthetic progestins non-interchangeable, and what individualized prescribing actually requires when a patient does not fit the commercial options.
The compounding debate does not have to stay murky. This is the clinical argument.
HRT University is a physiology-first clinical education program for licensed providers. Jointly accredited through Pinnacle Conference LLC (ACCME, ACPE, ANCC) for 30 CEUs.
Learn more about HRT University:https://bit.ly/4twBb0D
HRTU Newsletter:https://nicomislenp.kit.com/8050eeea5f
Join the HRT University Facebook Group:https://www.facebook.com/groups/1179376819949373/
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.